Treatment guidelines and early loss from care for people living with HIV in Cape Town, South Africa: A retrospective cohort study

1. United Nations Joint Programme on HIV/AIDS. The gap report. Geneva: United Nations Joint Programme on HIV/AIDS; 2014 [cited 2017 May 16]. http://www.refworld.org/docid/53f1e1604.html.

2. United Nations Joint Programme on HIV/AIDS. UNAIDS announces that the goal of 15 million people on life-saving HIV treatment by 2015 has been met nine months ahead of schedule. Geneva: United Nations Joint Programme on HIV/AIDS; 2015 [cited 2017 Jul 31]. http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/july/20150714_PR_MDG6report.

3. Katz IT, Bassett IV, Wright AA. PEPFAR in transition—implications for HIV care in South Africa. N Engl J Med. 2013;369(15):1385–7. doi: 10.1056/NEJMp1310982 24106930

4. U.S. President’s Emergency Plan for AIDS Relief. PEPFAR latest global results—2016. Washington (DC): U.S. President’s Emergency Plan for AIDS Relief; 2016 [cited 2017 May 15]. https://www.pepfar.gov/documents/organization/264882.pdf.

5. Nglazi MD, Lawn SD, Kaplan R, Kranzer K, Orrell C, Wood R, et al. Changes in programmatic outcomes during 7 years of scale-up at a community-based antiretroviral treatment service in South Africa. J Acquir Immune Defic Syndr. 2011;56(1):e1–8. doi: 10.1097/QAI.0b013e3181ff0bdc 21084996

6. South African Department of Health. The South African antiretroviral treatment guidelines—2010. Pretoria: South African Department of Health; 2010 [cited 2017 May 15]. http://apps.who.int/medicinedocs/documents/s19153en/s19153en.pdf.

7. Bekker LG, Venter F, Cohen K, Goemare E, Van Cutsem G, Boulle A, et al. Provision of antiretroviral therapy in South Africa: the nuts and bolts. Antivir Ther. 2014;19(Suppl 3):105–16. doi: 10.3851/IMP2905 25310359

8. Collins C, Beyrer C. Country ownership and the turning point for HIV/AIDS. Lancet Glob Health. 2013;1(6):e319–20. doi: 10.1016/S2214-109X(13)70092-5 25104588

9. South African Department of Health. National consolidated guidelines for the prevention of mother-to-child transmission of HIV (PMTCT) and the management of HIV in children, adolescents and adults Pretoria, South Africa. Pretoria: South African Department of Health; 2014 [cited 2017 May 15]. http://www.kznhealth.gov.za/family/HIV-Guidelines-Jan2015.pdf.

10. United Nations Joint Programme on HIV/AIDS. Country ownership for a sustainable AIDS response: from principles to practice. Geneva: United Nations Joint Programme on HIV/AIDS; 2012 [cited 2017 May 15]. http://www.unaids.org/sites/default/files/sub_landing/files/20120717_JC2134_UNAIDS_Country_Ownership_Discussion_Paper.pdf.

11. Fox MP, Rosen S. A new cascade of HIV care for the era of “treat all”. PLoS Med. 2017;14(4):e1002268. doi: 10.1371/journal.pmed.1002268 28399160

12. Cloete C, Regan S, Giddy J, Govender T, Erlwanger A, Gaynes MR, et al. The linkage outcomes of a large-scale, rapid transfer of HIV-infected patients from hospital-based to community-based clinics in South Africa. Open Forum Infect Dis. 2014;1(2):ofu058. doi: 10.1093/ofid/ofu058 25734128

13. Grimsrud A, Kaplan R, Bekker LG, Myer L. Outcomes of a nurse-managed service for stable HIV-positive patients in a large South African public sector antiretroviral therapy programme. Trop Med Int Health. 2014;19(9):1029–39. doi: 10.1111/tmi.12346 25041716

14. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, et al. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS. 2009;23(3):335–42. doi: 10.1097/QAD.0b013e328321823f 19114870

15. Njuguna C, Orrell C, Kaplan R, Bekker LG, Wood R, Lawn SD. Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS ONE. 2013;8(5):e63596. doi: 10.1371/journal.pone.0063596 23717451

16. Lawn SD, Kaplan R, Wood R, Bekker LG. Promoting retention in care: an effective model in an antiretroviral treatment service in South Africa. Clin Infect Dis. 2007;45(6):803. doi: 10.1086/521173 17712771

17. World Health Organization. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007 [cited 2017 Aug 3]. http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf.

18. Plazy M, Dray-Spira R, Orne-Gliemann J, Dabis F, Newell ML. Continuum in HIV care from entry to ART initiation in rural KwaZulu-Natal, South Africa. Trop Med Int Health. 2014;19(6):680–9. doi: 10.1111/tmi.12301 24654990

19. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8(7):e1001056. doi: 10.1371/journal.pmed.1001056 21811403

20. Clouse K, Pettifor AE, Maskew M, Bassett J, Van Rie A, Behets F, et al. Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013;62(2):e39–46. doi: 10.1097/QAI.0b013e318273ac48 23011400

21. Katz IT, Essien T, Marinda ET, Gray GE, Bangsberg DR, Martinson NA, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS. 2011;25(17):2177–81. doi: 10.1097/QAD.0b013e32834b6464 21832935

22. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015 [cited 2017 May 16]. http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/.

23. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830–9. doi: 10.1056/NEJMoa1600693 27424812

24. TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, Gabillard D, Badje A, Le Carrou J, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22. doi: 10.1056/NEJMoa1507198 26193126

25. Bor J, Herbst AJ, Newell ML, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science. 2013;339(6122):961–5. doi: 10.1126/science.1230413 23430655

26. Grinsztejn B, Hosseinipour MC, Ribpaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281–90. doi: 10.1016/S1473-3099(13)70692-3 24602844

27. Plazy M, Dabis F, Naidu K, Orne-Gliemann J, Barnighausen T, Dray-Spira R. Change of treatment guidelines and evolution of ART initiation in rural South Africa: data of a large HIV care and treatment programme. BMC Infect Dis. 2015;15 : 452. doi: 10.1186/s12879-015-1207-2 26497054

28. Haber N, Tanser F, Bor J, Naidu K, Mutevedzi T, Herbst K, et al. From HIV infection to therapeutic response: a population-based longitudinal HIV cascade-of-care study in KwaZulu-Natal, South Africa. Lancet HIV. 2017;4(5):e223–30. doi: 10.1016/S2352-3018(16)30224-7 28153470

29. Katz IT, Bogart LM, Cloete C, Crankshaw TL, Giddy J, Govender T, et al. Understanding HIV-infected patients’ experiences with PEPFAR-associated transitions at a Centre of Excellence in KwaZulu Natal, South Africa: a qualitative study. AIDS Care. 2015;27(10):1298–303. doi: 10.1080/09540121.2015.1051502 26300297

30. Katz IT, Dietrich J, Tshabalala G, Essien T, Rough K, Wright AA, et al. Understanding treatment refusal among adults presenting for HIV-testing in Soweto, South Africa: a qualitative study. AIDS Behav. 2015;19(4):704–14. doi: 10.1007/s10461-014-0920-y 25304330

31. Fox MP, Mazimba A, Seidenberg P, Crooks D, Sikateyo B, Rosen S. Barriers to initiation of antiretroviral treatment in rural and urban areas of Zambia: a cross-sectional study of cost, stigma, and perceptions about ART. J Int AIDS Soc. 2010;13 : 8. doi: 10.1186/1758-2652-13-8 20205930

32. Duff P, Kipp W, Wild TC, Rubaale T, Okech-Ojony J. Barriers to accessing highly active antiretroviral therapy by HIV-positive women attending an antenatal clinic in a regional hospital in western Uganda. J Int AIDS Soc. 2010;13 : 37. doi: 10.1186/1758-2652-13-37 20863399

33. Katz IT, Dietrich JJ, Bogart LM, Leone D, Courtney I, Tshabalala G, et al. A prospective multi-site cohort study of pre-ART losses and ART refusal in South Africa. Abstract number 1014. Conference on Retroviruses and Opportunistic Infections; 2016 Feb 22–25; Boston, MA, US. 2016 [cited 2017 Oct 13]. http://www.croiconference.org/sessions/prospective-multisite-cohort-study-pre-art-losses-and-art-refusal-south-africa.

34. Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012;17 : 1509–20. doi: 10.1111/j.1365-3156.2012.03089.x 22994151

35. Lippman SA, Shade SB, El Ayadi AM, Gilvydis JM, Grignon JS, Liegler T, et al. Attrition and opportunities along the HIV care continuum: findings from a population-based sample, North West Province, South Africa. J Acquir Immune Defic Syndr. 2016;1;73(1):91–9. doi: 10.1097/QAI.0000000000001026 27082505

36. Fox MP, Shearer K, Maskew M, Meyer-Rath G, Clouse K, Sanne I. Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS ONE. 2014;9(10): e110252. doi: 10.1371/journal.pone.0110252 25330087